Showing 6281-6290 of 9848 results for "".
- Dr. Alice Gottlieb to Share Hidradenitis Suppurativa Findings at AAD Annual Meetinghttps://practicaldermatology.com/news/dr-alice-gottlieb-to-share-hidradenitis-suppurativa-findings-at-aad-annual-meeting/2459916/Alice Gottlieb, MD, PhD will be presenting “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS), Including Marked Reduction in Pain” during the afternoon session on March 2, 2019 at the American Academy of Dermatology annual meeting being held at the Walter E. Washing
- 2019 Residents of Distinction Return from Caribbean Dermatology Symposiumhttps://practicaldermatology.com/news/2019-residents-of-distinction-return-from-caribbean-dermatology-symposium/2459919/Five dermatology residents have just returned from the 18th Annual Caribbean Dermatology Symposium, held in Grand Cayman Island. Their participation was sponsored by Beiersdorf Inc., as part of the dermMentors™ Resident of Distinction Award™ program. The reside
- Encore Dermatology Shares Positive Pivotal Study Results for Impoyz for the Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/encore-dermatology-shares-positive-pivotal-study-results-for-impoyz-for-the-treatment-of-plaque-psoriasis/2459920/Impoyz Cream (clobetasol propionate) Cream, 0.025% demonstrated efficacy early with 14.2 percent of Impoyz patients achieving treatment success at day 8 versus 1.6 percent in the vehicle group, according to results of a pivitol study that were shared at the 15 th annual Maui Derm Conference. Trea
- New Data Show Cosentyx Improves Quality of Life in Patients Being Treated for Psoriasishttps://practicaldermatology.com/news/new-data-show-cosentyx-improves-quality-of-life-in-patients-being-treated-for-psoriasis/2459924/Novartis shared results from a pooled analysis of four Phase 3 clinical trials demonstrating patients with moderate to severe plaque psoriasis (PsO) treated with Cosentyx (secukinumab) 300mg reported improvements in mobility, self-care, and usual activities components of the EQ-5D-3L questionnair
- RealSelf Survey: 36 Percent of US Adults Are Considering Cosmetic Treatmentshttps://practicaldermatology.com/news/realself-36-percent-of-us-adults-are-considering-cosmetic-treatments/2459933/More than four in five U.S. adults want to improve their personal well-being or appearance in 2019, and 36 percent are considering cosmetic treatments, according to new RealSelf survey. Fully 82 percent of U.S. adults plan to make changes related to their personal well-being and/or appear
- Almirall's Seysara Now Availablehttps://practicaldermatology.com/news/seysara-now-available/2459932/SeysaraTM (sarecycline), a novel tetracycline-derived oral antibiotic developed specifically for the treatment of acne, is now commercially available from Almirall. Seysara™ was approved in October by FDA for the treatment of moderate to severe non-nodular inflammatory acne
- New Review Highlights Comprehensive Treatment Guidelines for Severe ADhttps://practicaldermatology.com/news/new-review-highlights-comprehensive-treatment-guidelines-for-severe-ad/2459936/A team of investigators from the University of Colorado College of Nursing at CU Anschutz Medical Campus and National Jewish Health has identified comprehensive guidelines for managing severe atopic dermatitis (AD). The
- Study: States with Fewer Melanoma Diagnoses Have Higher Death Rateshttps://practicaldermatology.com/news/study-states-with-fewer-melanoma-diagnoses-have-higher-death-rates/2459937/States with fewer melanoma diagnoses actually have higher death rates, report researchers at University of Utah Health. The researchers conducted a state-by-state analysis to understand the geographic disparities for patients diagnosed with melanoma. They found lower survival is associate
- Peak Health Launches Plant-Based Regenerative Skincare Linehttps://practicaldermatology.com/news/peak-health-launches-plant-based-regenerative-skincare-line/2459940/Peak Health, launched Curere, a patented, regenerative skin care line created to treat a range of skin conditions, including acne, third-degree burns and necrosis. The line is made from all-natural ingredients to penetrate the dermal layer of skin and activate stem cells while also facili
- “Outstanding Clearance Rates” for Sebaceous Hyperplasia Facial Lesions Seen with NPShttps://practicaldermatology.com/news/outstanding-clearance-rates-for-sebaceous-hyperplasia-facial-lesions-seen-with-nps/2459943/Pulse Biosciences' Nano-Pulse Stimulation (NPS) technology achieved “outstanding clearance rates” on sebaceous hyperplasia lesions on the face, the company reports. Initial data indicate that 221 of 222 (99.5 percent